Lung Cancer: A Review
DOI:
https://doi.org/10.61841/c5x6th67Keywords:
Mass Screening, Primary Lung Cancer, Radiograph, TumorAbstract
CT has been used recently in lung cancer mass screening. Small cancers have been identified, but these lesions do not completely recognize the growth properties of the lesions. In the three year mass CT screening program, researchers found 82 primary cancers, 61 of which were studied in present study. The volume doubling time has been determined on the basis of the exponential model using successive yearly CT images. Both cases of high resolution CT (HRCT) were also examined in the hospital. Lesions were classified into three HRCT-based types: type GS (n519), ground glass opacity (GGO); focal GGO with a solid central component; type G (n519) and solid nodule. The standard chest X-were not found in 18 (95 percent) lesions of type G, 18 (95 percent) of type GS and 7 (30 percent) of type S. For type G, type GS and type S, the maximum tumor size was 10, 11 mm and 16 mm, respectively. Adenocarcinomas were the majority of (80%) tumors; 78% were GGO ( GS and type G). The mean value of VDT for type G, GS, and type S was 813 days, 457 days and 149 days; these are somewhat far apart from each other (p.0.05). Our findings suggest that an annual CT mass screening for 3 consecutive years resulted in the recognition of several adenocarcinomas, not apparent in chestx-rays that are slowly increasing.
Downloads
References
[1] P. C. Registry, “Global Cancer Observatory,” Malaysia Cancer Stat., 2019.
[2] F. Nasim, B. F. Sabath, and G. A. Eapen, “Lung Cancer,” Medical Clinics of North America. 2019.
[3] I. Monnet, “Small cell lung cancer,” Rev. des Mal. Respir. Actual., 2018.
[4] The Global Cancer Observatory, “Cancer fact sheet,” World Heal. Organ., 2019.
[5] Canadian Cancer Statistics Advisory Committee, Canadian Cancer Statistics 2019. 2019.
[6] P. M. de Groot, C. C. Wu, B. W. Carter, and R. F. Munden, “The epidemiology of lung cancer,” Translational Lung Cancer Research. 2018.
[7] L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal, “Global cancer statistics, 2012,” CA. Cancer J. Clin., 2015.
[8] L. A. Torre, R. L. Siegel, and A. Jemal, “Lung cancer statistics,” Adv. Exp. Med. Biol., 2016.
[9] C. S. Dela Cruz, L. T., and R. A. Matthay, “Lung Cancer: Epidemiology, Etiology, and Prevention,” Clinics in Chest Medicine. Tanoue 2011.
[10] D. R. Aberle et al., “Reduced lung-cancer mortality with low-dose computed tomographic screening,” N. Engl. J. Med., 2011.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
